Ortho Clinical Diagnostics Presents Cardiac Advances at EuroMedLab 2019
|
By LabMedica International staff writers Posted on 20 May 2019 |

Image: The Multi-Test VITROS chemistry product slides (Photo courtesy of Ortho Clinical Diagnostics).
Ortho Clinical Diagnostics (Raritan, NJ, USA) sponsored an educational workshop on high-sensitivity troponin assays and presented five scientific posters at EuroMedLab 2019, the 23rd IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicine, which took place from May 19-23, 2019, at the CCIB - Centre Convencions Internacional in Barcelona. Ortho also displayed its new multi-test VITROS Chemistry Product Slides, the VITROS Cell, a compact automation solution allowing two VITROS XT 7600 instruments (launched in 2018) to operate as a seamless solution, and the VITROS XT 7600 Integrated System at its booth during the congress.
Ortho, an in vitro diagnostics company serving the clinical laboratory and immunohematology communities, offers sophisticated testing technologies, automation, information management and interpretation tools to clinical laboratories around the world to help them run more efficiently and effectively and improve patient care. Ortho's high-quality products and services enable health care professionals to make better-informed treatment decisions across hospitals, hospital networks, blood banks and labs in more than 125 countries and territories.
In addition to the educational workshop, "The Clinical Use and Performance of High-Sensitivity Troponin Assays with the Esc 0-1 Algorithm: Overcoming Challenges in Implementation," Ortho presented the following five scientific posters at EuroMedLab:
- Evaluation of the New Multi-Test VITROS Chemistry Product Slides on the VITROS XT 7600 Integrated System
- Sigma Metrics for Assessing the Analytical Quality of the New Multi-Test VITROS XT Chemistry Products Slides
- Precision of the New Multi-Test VITROS Chemistry Product Slides on the VITROS XT 7600 Integrated System
- Performance Evaluation of the VITROS hs Troponin I Assay on the VITROS ECi/ECiQ and 3600 Immunodiagnostic and VITROS 5600/XT 7600 Integrated Systems
- Performance Evaluation of the VITROS Immunodiagnostic Products B·R·A·H·M·S PCT Assay on the VITROS 3600 Immunodiagnostic System
"Ortho is committed to staying ahead of the rapidly evolving clinical lab environment," said Joan Martin, executive vice president and head of Ortho's EMEA region." At this year's EuroMedLab, we're proud to be presenting data on two of our just-launched, key product offerings: our new high-sensitivity troponin assay and Ortho's VITROS XT MicroSlide. The XT MicroSlide can perform two tests simultaneously to improve lab workflow performance, productivity and clinical outcomes."
Ortho, an in vitro diagnostics company serving the clinical laboratory and immunohematology communities, offers sophisticated testing technologies, automation, information management and interpretation tools to clinical laboratories around the world to help them run more efficiently and effectively and improve patient care. Ortho's high-quality products and services enable health care professionals to make better-informed treatment decisions across hospitals, hospital networks, blood banks and labs in more than 125 countries and territories.
In addition to the educational workshop, "The Clinical Use and Performance of High-Sensitivity Troponin Assays with the Esc 0-1 Algorithm: Overcoming Challenges in Implementation," Ortho presented the following five scientific posters at EuroMedLab:
- Evaluation of the New Multi-Test VITROS Chemistry Product Slides on the VITROS XT 7600 Integrated System
- Sigma Metrics for Assessing the Analytical Quality of the New Multi-Test VITROS XT Chemistry Products Slides
- Precision of the New Multi-Test VITROS Chemistry Product Slides on the VITROS XT 7600 Integrated System
- Performance Evaluation of the VITROS hs Troponin I Assay on the VITROS ECi/ECiQ and 3600 Immunodiagnostic and VITROS 5600/XT 7600 Integrated Systems
- Performance Evaluation of the VITROS Immunodiagnostic Products B·R·A·H·M·S PCT Assay on the VITROS 3600 Immunodiagnostic System
"Ortho is committed to staying ahead of the rapidly evolving clinical lab environment," said Joan Martin, executive vice president and head of Ortho's EMEA region." At this year's EuroMedLab, we're proud to be presenting data on two of our just-launched, key product offerings: our new high-sensitivity troponin assay and Ortho's VITROS XT MicroSlide. The XT MicroSlide can perform two tests simultaneously to improve lab workflow performance, productivity and clinical outcomes."
Latest Industry News
- New Collaboration Expands Point-of-Care Testing Across UK Community Pharmacies
- New Collaboration Advances Precision Oncology Screening for Lung Cancer in Japan
- AI-Powered Pathology Collaboration Supports Companion Diagnostic Development
- Strategic Collaboration Expands Commercial Access to Oncology Companion Diagnostics
- Collaboration Supports Global ADC Development with AI-Powered Tissue Analysis
- Standardized Staining Technology Advances Digital Pathology Workflows
- Global Testing Service Advances Leukemia MRD Monitoring
- Ultrasensitive MRD Assay Gains Medicare Coverage for Immunotherapy and Breast Cancer Monitoring
- Genprex and Roche Collaborate on AI-Driven NSCLC Biomarker Testing
- Collaboration Explores Clinical Use of Single-Cell and Spatial Technologies
- Partnership Brings Automated Pathology Archiving Solutions to U.S. Labs
- New Collaboration Integrates Low-Code Automation into Laboratory Platform
- LumiQuick Advances Oxidative Stress Research with Expanded AOXRE Portfolio
- Collaboration Advances Extracellular Vesicle-Based Tests for Neurodegenerative Diseases
- Collaboration Advances Sputum-Based Diagnostics for Asthma and COPD
- Tempus to Acquire Personalis in $1.5 Billion Precision Oncology Deal
Channels
Clinical Chemistry
view channel
Blood Test Measures Amyloid Seeding Activity to Detect Alzheimer’s Disease
Early, accurate diagnosis of Alzheimer’s disease (AD) remains challenging in routine practice, despite its role as the leading cause of dementia worldwide. Confirmation typically relies on cerebrospinal... Read more
Blood Test Markers Could Help Identify Older Adults at Risk of Disability
Maintaining independence into very old age is a growing public health challenge as Japan’s population rapidly ages. Nearly 60% of Japanese adults aged 85 years and older already receive support through... Read moreMolecular Diagnostics
view channel
New Liquid Biopsy Approach Shows Promise for Detecting Breast Cancer Recurrence
Many liquid biopsy strategies for monitoring breast cancer recurrence focus on detecting genetic mutations in tumor DNA. Researchers are evaluating whether additional features of circulating cell-free... Read more
Whole-Blood RNA Test Could Improve Breast Cancer Screening in Dense Breasts
Breast cancer screening continues to face challenges, including limited detection of small tumors and uneven participation, particularly among women with dense breasts. These limitations can leave diagnostic... Read moreHematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read moreImmunology
view channel
AI-Based Antibody Profiling Predicts Strength of COVID-19 Vaccine Response
Vaccine-induced protection can vary widely between individuals, creating uncertainty for clinicians, particularly in patients with immunosuppressive conditions. Demographic and health factors explain only... Read more
Immune Biomarkers May Predict Recurrent Checkpoint Inhibitor Arthritis
Inflammatory arthritis is a recognized immune-related adverse event in patients treated with immune checkpoint inhibitors (ICIs) for cancer. Between 20% and 50% of affected patients experience more than... Read moreMicrobiology
view channel
Genetic Marker Identifies Emerging Resistance to Frontline Malaria Drugs
Artemisinin-based combination therapy remains central to controlling Plasmodium falciparum malaria, but emerging drug resistance is complicating treatment and surveillance. In Uganda and across sub-Saharan... Read more
Surveillance and Susceptibility Testing Track Rising Candida Auris in U.S.
Drug-resistant fungal infections are straining infection control and treatment in hospitals and long-term care facilities, where rapid transmission can lead to severe outcomes. Candida auris has expanded... Read morePathology
view channel
AI-Pathologist Framework Improves Accuracy and Reliability in Cancer Diagnosis
Ensuring reliable cancer diagnosis from digital pathology remains a critical challenge as clinical decisions rely on accurate slide interpretation. While artificial intelligence (AI) has accelerated whole-slide... Read more
New Review Highlights Intelligent Agents as Next Step for Digital Pathology
Digital pathology remains constrained by models that classify single images without mirroring how clinicians interrogate multiple slides, adjust magnification, and synthesize ancillary tests.... Read more
Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism
Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read moreTechnology
view channel
Autonomous Robotic System Receives FDA Authorization for Blood Collection
Venipuncture is central to many diagnostic pathways, but routine blood collection can be affected by staffing constraints and procedural variability that influence consistency and patient experience.... Read more







